OmicsDI
Toggle navigation
Browse
Submit Data
Databases
API
Advanced
Search
57
Results
Show all
Save search
Copy query
Show results for
Unknown
(57)
Publication Date
Release Date
2015
(11)
2016
(8)
2022
(6)
2017
(6)
2025
(5)
2023
(5)
2018
(5)
2021
(3)
2020
(2)
2019
(2)
2014
(1)
2013
(1)
2006
(1)
2000
(1)
Previous
page
1 / 6
You're on page
1
page
2
page
3
page
4
page
5
page
6
Next
page
Sort
by:
Relevance
Page size
10
Epigenetics as a mechanism driving polygenic clinical drug resistance.
Not available
S-EPMC2361257
|
biostudies-literature
Cite
Overall survival with maintenance olaparib in platinum-sensitive relapsed ovarian cancer by somatic or germline BRCA and homologous recombination repair mutation status.
Not available
S-EPMC11997082
|
biostudies-literature
Cite
Structural Variants at the <i>BRCA1/2</i> Loci are a Common Source of Homologous Repair Deficiency in High-grade Serous Ovarian Carcinoma.
Not available
S-EPMC7610896
|
biostudies-literature
Cite
The Case Manager: An Agent Controlling the Activation of Knowledge Sources in a FHIR-Based Distributed Reasoning Environment.
Not available
S-EPMC10499504
|
biostudies-literature
Cite
Computer support for interpreting family histories of breast and ovarian cancer in primary care: comparative study with simulated cases.
Not available
S-EPMC27423
|
biostudies-literature
Cite
Phase 2 multicentre trial investigating intermittent and continuous dosing schedules of the poly(ADP-ribose) polymerase inhibitor rucaparib in germline BRCA mutation carriers with advanced ovarian and breast cancer.
Not available
S-EPMC4882768
|
biostudies-literature
Cite
Common variants at the CHEK2 gene locus and risk of epithelial ovarian cancer.
Not available
S-EPMC4635670
|
biostudies-literature
Cite
Quality of life from cytoreductive surgery in advanced ovarian cancer: Investigating the association between disease burden and surgical complexity in the international, prospective, SOCQER-2 cohort study.
Not available
S-EPMC9306902
|
biostudies-literature
Cite
Phase 3 clinical trials evaluating poly(ADP-ribose) polymerase inhibition plus immunotherapy for first-line treatment of advanced ovarian cancer.
Not available
S-EPMC12578505
|
biostudies-literature
Cite
Efficacy and Safety of Weekly Paclitaxel Plus Vistusertib vs Paclitaxel Alone in Patients With Platinum-Resistant Ovarian High-Grade Serous Carcinoma: The OCTOPUS Multicenter, Phase 2, Randomized Clinical Trial.
Not available
S-EPMC10020933
|
biostudies-literature
Cite
Previous
page
1 / 6
You're on page
1
page
2
page
3
page
4
page
5
page
6
Next
page
Sort
by:
Relevance
Page size
10
OmicsDI
is part of the ELIXIR infrastructure
OmicsDI is an Elixir interoperability service.
Learn more ›
Tweets